Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics and Efficacy of Renin Inhibitors

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The successful introduction of angiotensin converting enzyme (ACE) inhibitors in the treatment of patients with essential hypertension or heart failure has increased interest in the (patho)physiological role of the renin-angiotensin system (RAS). ACE is not only involved in the formation of angiotensin II from angiotensin I, but also inactivates vasoactive substances such as bradykinin and substance P. Accumulation of these substances during treatment with ACE inhibitors may contribute to both their therapeutic action and certain adverse effects associated with their use, such as cough and angioneurotic oedema.

Renin inhibitors offer an alternative approach to inhibit the RAS. The major advantage of these, still experimental, drugs is their high specificity for the RAS since angiotensinogen is the only known substrate of renin. The currently available renin inhibitors are pseudopeptides that are rapidly taken up by the liver and excreted in the bile. Consequently, these drugs are subjected to a considerable first pass effect which limits their oral bioavailability. Additionally, plasma elimination half-life times are short and the duration of action is limited. Despite these shortcomings, single oral or intravenous administration results in a 80 to 90% inhibition of plasma renin activity and a slight reduction in blood pressure in patients with hypertension. The extent of blood pressure reduction is dependent on the patient’s salt balance.

After 1 week of oral treatment with the renin inhibitor remikiren, the antihypertensive effect was reduced in salt-repleted hypertensive patients. Subsequent intravenous administration of the drug did not further affect blood pressure, indicating that it was not the first pass effect that was limiting the efficacy of remikiren. The reactive increase in immunoreactive renin, alternative routes of angiotensin II formation and counteracting blood pressure regulating mechanisms may also be involved in the limited haemodynamic response to renin inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Campbell DJ. Chapter 23: metabolism of prorenin, renin, angiotenisogen, and angiotensins by tissues. In: Robertson JIS, Nicholls MG, editors. The renin-angiotenins system. London: Gower Medical Publishing, 1993; 1–23

    Google Scholar 

  2. Opsahl JA, Smith KL, Murray RD, et al. Renin and renin inhibition in anephric man. Clin Exp Hypertens 1993; 15: 289–306

    Article  PubMed  CAS  Google Scholar 

  3. Campbell DJ, Kladis A, Duncan AM. Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension 1993; 22: 513–22

    Article  PubMed  CAS  Google Scholar 

  4. Kurtz A, Scholz H, Della Bruna R. Molecular mechanisms of renin release. J Cardiovasc Pharmacol 1990; 16 Suppl. 4: S1–S7

    Article  PubMed  CAS  Google Scholar 

  5. Stella A, Zanchetti A. Chapter 22: elimination of renin, prorenin, and angiotensins by the kidney: renin in urine. In: Robertson JIS, Nicholls MG, editors. The renin-angiotensin system. London: Gower Medical Publishing, 1993; 1–8

    Google Scholar 

  6. Page IH, McSwain B, Knapp GM, et al. The origin of renin activator. Am J Physiol 1941; 135: 214–22

    CAS  Google Scholar 

  7. Schneider EG, Rostorfer HH, Nash FD. Distribution volume and metabolic clearance rate of renin in anesthetized nephrectomized dogs. Am J Physiol 1968; 215: 1115–22

    PubMed  CAS  Google Scholar 

  8. Campbell DJ, Kladis A, Skinner SL, et al. Characterization of angiotensin peptides in plasma of anephric man. J Hypertens 1991; 9: 265–74

    Article  PubMed  CAS  Google Scholar 

  9. Dzau V, Pratt RE. Cardiac, vascular, and intrarenal renin-angiotensin systems in normal physiology and disease. In: Robertson JIS, Nicholls MG, editors. The renin-angiotensin system. London: Gower Medical, 1993; 42: 1–11

    Google Scholar 

  10. Campbell DJ. The site of angiotensin production. J Hypertens 1990; 3: 199–207

    Article  Google Scholar 

  11. Hirsch AT, Talsness CE, Schunkert H, et al. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991; 69: 475–82

    Article  PubMed  CAS  Google Scholar 

  12. Carretero OA, Scicli AG. Kinins paracrine hormone. Kidney International 1988; 34 Suppl. 26: S52-S59

    Google Scholar 

  13. Lindsey CJ, Bendhack LM, Paiva ACM. Effects of teprotide, captopril and enalaprilat on arterial wall kininase and angiotensin converting enzyme activity. J Hypertens 1987; 5 Suppl. 2: S71-S76

    Google Scholar 

  14. Marks ES, Bing RF, Thurston H, et al. Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14 225): the role of factors other than renin-angiotensin blockade in the rat. Clin Sci 1980; 58: 1–6

    PubMed  CAS  Google Scholar 

  15. Quilley J, Duchin KL, Hudes EM, et al. The antihypertensive effect of captopril in essential hypertension: relationship to prostaglandins and the kallikrein-kinin system. J Hypertens 1987; 5: 121–8

    Article  PubMed  CAS  Google Scholar 

  16. Vallance P, Collier J, Moncada S. Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo. Cardiovasc Res 1989; 23: 1053–7

    Article  PubMed  CAS  Google Scholar 

  17. Mitchell JA, Denucci G, Warner TD, et al. Different patterns of release of endothelium-derived relaxing factor and pro-stacyclin. Br J Pharmacol 1992; 105: 485–9

    Article  PubMed  CAS  Google Scholar 

  18. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between pro-stacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639–46

    Article  PubMed  CAS  Google Scholar 

  19. Cooke JP, Rossitch Jr E, Andon NA, et al. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest 1991; 88: 1663–71

    Article  PubMed  CAS  Google Scholar 

  20. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302

    Article  Google Scholar 

  21. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91

    Article  Google Scholar 

  22. Zanchetti A. The clinical role of angiotensin converting enzyme inhibitors in antihypertensive therapy in the 1990s. J Hypertens 1989; 7 Suppl. 5: S37-S40

    Google Scholar 

  23. Hajjali AF, Wong PC. Beta-adrenoceptor blockade in rabbit inhibits the renin-releasing effect of AT(1)-receptor antagonist losartan. J Pharmacol Exp Ther 1993; 267: 1423–7

    CAS  Google Scholar 

  24. Kitami Y, Hiwada K, Murakami E, et al. The effect of the renin inhibitor ES-1005 on the expression of the kidney renin gene in sodium-depleted marmosets. J Hypertens 1990; 8: 1143–6

    Article  PubMed  CAS  Google Scholar 

  25. Corvol P, Menard J. Renin inhibition: immunological procedures and renin inhibitor peptides. Kidney Int 1988; 34 Suppl. 26: S73-S79

    Google Scholar 

  26. Burton J, Cody Jr RJ, Herd JA, et al. Specific inhibition of renin by an angiotensin analog: studies in sodium depletion and renin-dependent hypertension. Proc Natl Acad Sci USA 1980; 77: 5476–9

    Article  PubMed  CAS  Google Scholar 

  27. Gross F, Lazar J, Orth H. Inhibition of the renin-angiotensin reaction by pepstatin. Science 1972; 175: 656

    Article  PubMed  CAS  Google Scholar 

  28. Hui KY, Haber E. Chapter 85: renin inhibitors. In: Robertson JIS, Nicholls MG, editors. The renin-angiotensin system. London: Gower Medical, 1993; 1–14

    Google Scholar 

  29. Zusman RM, Burton J, Christensen D, et al. Hemodynamic effects of a competitive renin inhibitory peptide in humans: evidence for multiple mechanisms of action. Trans Assoc Am Physicians 1983; 96: 365–74

    PubMed  CAS  Google Scholar 

  30. Webb DJ, Manhem PJ, Ball SG, et al. A study of the renin inhibitor H142 in man. J Hypertens 1985; 3: 653–8

    Article  PubMed  CAS  Google Scholar 

  31. van den Meiracker AH, Admiraal PJJ, Man in’t Veld AJ, et al. Prolonged blood pressure reduction by orally active renin inhibitor Ro 42-5892 in essential hypertension. BMJ 1990; 301: 205–10

    Article  PubMed  Google Scholar 

  32. Glassman HN, Kleinen HD, Boger RS, et al. Clinical pharmacology of enalkiren, a novel dipeptide renin inhibitor. J Cardiovasc Pharmacol 1990; 16 Suppl. 4: S76–S813

    Article  PubMed  Google Scholar 

  33. Kokubu T, Hiwada K, Murakami E, et al. ES-8891, an orally active inhibitor of human renin. Hypertension 1990; 15: 909–13

    Article  PubMed  CAS  Google Scholar 

  34. Nussberger J, Delabays A, de Gasparo M, et al. Hemodynamic and biochemical consequences of renin inhibition by infusion ofCGP38560A in normal volunteers. Hypertension 1989; 13: 948–53

    Article  PubMed  CAS  Google Scholar 

  35. Denolle T, Luo P, Guyene TT, et al. Acute effects of a pseudotetrapeptide as renin inhibitor on blood pressure and renin-angiotensin system of sodium-repleted and sodium-depleted hypertensive patients. Arzneimittelforschung 1993; 43: 255–9

    PubMed  CAS  Google Scholar 

  36. Zusman RM, Hui KY, Nussberger J, et al. R-PEP-27, a potent renin inhibitor, decreases plasma angiotensin II and blood pressure in normal volunteers. Am J Hypertens 1994; 7: 295–301

    PubMed  CAS  Google Scholar 

  37. Ogihara T, Nagano M, Higaki J, et al. Antihypertensive efficacy of FK906, a novel human renin inhibitor. Clin Ther 1993; 15: 539–48

    PubMed  CAS  Google Scholar 

  38. Kleinbloessem CH, Weber C, Fahrner E, et al. Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin Pharmacol Ther 1993; 53: 585–92

    Article  Google Scholar 

  39. Gupta SK, Granneman GR, Boger RS, et al. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor), I: Single dose study. Drug Metab Dispos Biol Fate Chem 1992; 20: 821–5

    PubMed  CAS  Google Scholar 

  40. Gupta SK, Granneman GR, Packer M, et al. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor), II: a dose-ranging study in patients with congestive heart failure. J Cardiovasc Pharmacol 1993; 21: 834–40

    Article  PubMed  CAS  Google Scholar 

  41. Kleinen HD, Rosenberg SH, Baker WR, et al. Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science 1992; 257: 1940–3

    Article  Google Scholar 

  42. Weber C, Birnbock H, Leube J, et al. Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. Br J Clin Pharmacol 1993; 36: 547–54

    Article  PubMed  CAS  Google Scholar 

  43. Weber C, Roos B, Birnboeck H, et al. Effect of food on the oral bioavailability of the renin inhibitor remikiren (Ro 42-5892) [abstract]. Br J Clin Pharmacol 1993; 36: 177P-8P

    Article  Google Scholar 

  44. de Gasparo M, Cumin F, Nussberger J, et al. Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol 1989; 27: 587–96

    Article  PubMed  Google Scholar 

  45. Cumin F, Schnell C, Richert P, et al. Pharmacokinetics and tissue distribution of the renin inhibitor N-(2-(R)-benzyl-3-tert-buty l-sulfonyl-propionyl)-His-ChacVal-n-butylamine in marmosets. Drug Metab Dispos Biol Fate Chem 1990; 18: 831–5

    PubMed  CAS  Google Scholar 

  46. Corvol P, Chauveau D, Jeunemaitre X, et al. Human renin inhibitor peptides. Hypertension 1990; 16: 1–11

    Article  PubMed  CAS  Google Scholar 

  47. Clozel JP, Fischli W. Comparative effects of three different potent renin inhibitors in primates. Hypertension 1993; 22: 9–17

    Article  PubMed  CAS  Google Scholar 

  48. Wood JM, Criscione L, de Gasparo M, et al. CGP 38 560: orally active, low molecular weight renin inhibitor with high potency and specificity. J Cardiovasc Pharmacol 1989; 14: 221–6

    Article  PubMed  CAS  Google Scholar 

  49. Clozel JP, Fischli W. Discovery of remikiren as the first orally active renin inhibitor. Arzneimittelforschung 1993; 43: 260–2

    PubMed  CAS  Google Scholar 

  50. Ziegler K, Seeberger A. Hepatocellular uptake of peptides, I: Carrier-mediated uptake of hydrophilic linear peptides with renin inhibitory activity into isolated rat liver cells. Biochem Pharmacol 1993; 45: 909–16

    Article  PubMed  CAS  Google Scholar 

  51. Seeberger A, Ziegler K. Hepatocellular uptake of peptides, II: Interactions between hydrophilic linear renin-inhibiting peptides and transport systems for endogenous substrates in liver cells. Biochem Pharmacol 1993; 45: 917–25

    Article  PubMed  CAS  Google Scholar 

  52. Kleinert HD, Stein HH, Boyd S, et al. Discovery of a well-absorbed, efficacious renin inhibitor, A-74273. Hypertension 1992; 20: 768–75

    Article  PubMed  CAS  Google Scholar 

  53. Kararli TT, Needham TE, Griffin M, et al. Oral delivery of a renin inhibitor compound using emulsion formulations. Pharm Res 1992; 9: 888–93

    Article  PubMed  CAS  Google Scholar 

  54. Sheehy AM, Hoover JL, Rush BD, et al. Intrapulmonary delivery of renin inhibitory peptides results in sustained release because of saturable transport. Pharm Res 1993; 10: 1548–51

    Article  PubMed  CAS  Google Scholar 

  55. Doig JK, MacFadyen RJ, Meredith PA, et al. Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. J Cardiovasc Pharmacol 1992; 20: 875–80

    Article  PubMed  CAS  Google Scholar 

  56. van den Meiracker AH, Admiraal PJJ, Derkx FHM, et al. Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. J Hypertens 1993; 11: 831–8

    Article  PubMed  Google Scholar 

  57. Rongen GA, Lenders JWM, Kleinbloesem CH, et al. Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension. Clin Pharmacol Ther 1993; 54: 567–77

    Article  PubMed  CAS  Google Scholar 

  58. Kobrin I, Viskoper RJ, Laszt A, et al. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertens 1993; 6: 349–56

    PubMed  CAS  Google Scholar 

  59. Schalekamp MA, Derkx FH, van den Meiracker AH. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system. J Hypertens 1992; 10 Suppl.: S157–S164

    Article  CAS  Google Scholar 

  60. Jeunemaitre X, Menard J, Nussberger J, et al. Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am J Hypertens 1989; 2: 819–27

    PubMed  CAS  Google Scholar 

  61. Menard J, Guyene T, Chatellier G, et al. Renin release regulation during acute renin inhibition in normal volunteers. Hypertension 1991; 18: 257–65

    Article  PubMed  CAS  Google Scholar 

  62. Camenzind E, Nussberger J, Juilerat L, et al. Effect of renin response during renin inhibition: oral Ro 42-5892 in normal humans. J Cardiovasc Pharmacol 1991; 18: 299–307

    Article  PubMed  CAS  Google Scholar 

  63. Ii Y, Murakami E, Hiwada K. Effect of renin inhibitor, ES-8891, on renal renin secretion and storage in the marmoset: comparison with captopril. J Hypertens 1991; 9: 1119–25

    PubMed  CAS  Google Scholar 

  64. Murakami E, Kokubu T, Ii Y, et al. Effects of repeated oral administration of renin inhibitor ES-8891 on the renin-angiotensin system in human subjects. Hypertens Res 1992; 15: 41–4

    Article  CAS  Google Scholar 

  65. Delabays A, Nussberger J, Porchet M, et al. Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension 1989; 13: 941–7

    Article  PubMed  CAS  Google Scholar 

  66. Weber MA, Neutel JM, Essinger I, et al. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation 1990; 81: 1768–74

    Article  PubMed  CAS  Google Scholar 

  67. van den Meiracker AH, Admiraal PJ, Man in’t Veld AJ, et al. Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension. BMJ 1990; 301: 205–10

    Article  PubMed  Google Scholar 

  68. Boger RS, Glassman HN, Cavanaugh JH, et al. Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension. Hypertension 1990; 15: 835–40

    Article  PubMed  CAS  Google Scholar 

  69. Neuberg GW, Kukin ML, Penn J, et al. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. Am J Cardiol 1991; 67: 63–6

    Article  PubMed  CAS  Google Scholar 

  70. Morice AH, Lowry R, Brwon MJ, et al. ACE and the cough reflex. Lancet 1987; ii: 1116–8

    Article  Google Scholar 

  71. Mento PF, Holt WF, Murphy WR, et al. Combined renin and converting enzyme inhibition in rats. Hypertension 1989; 13: 741–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, PO Box 9101, 6500 HB, Nijmegen, The Netherlands

    Gerard A. Rongen,  Jacques W. M. Lenders, Paul Smits & Theo Thien

Authors
  1. Gerard A. Rongen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacques W. M. Lenders
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Smits
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Theo Thien
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rongen, G.A., Lenders, J.W.M., Smits, P. et al. Clinical Pharmacokinetics and Efficacy of Renin Inhibitors. Clin-Pharmacokinet 29, 6–14 (1995). https://doi.org/10.2165/00003088-199529010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199529010-00002

Keywords

Search

Navigation